Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Huth

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Drug Metabolism and Personalized Therapy|October 9, 2016
Improvement of the chemical inhibition phenotyping assay by cross-reactivity correctionNicholas M Njuguna, Ken-Ichi Umehara, Felix Huth, et al.
Drug Metabolism and Personalized Therapy|May 31, 2019
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissionsKenichi Umehara, Felix Huth, Yi Jin, et al.
Clinical and Translational Science|June 27, 2026
PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of SiponimodFelix Huth, Kasra Shakeri-Nejad, Anne Gardin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 15, 2024
Improving In Vitro-In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound MoleculesMarkus Trunzer, Joana Teigão, Felix Huth, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 13, 2019
Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical modelsJulia Riede, Ken-Ichi Umehara, Patrick Schweigler, et al.
Journal of Pharmaceutical Sciences|February 4, 2021
Predicting Oral Absorption for Compounds Outside the Rule of Five Property SpaceFelix Huth, Norbert Domange, Birk Poller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 23, 2024
Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major MetabolitesUlrike Glaenzel, Felix Huth, Fabian Eggimann, et al.
Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 10, 2019
A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant TransportersPéter Tátrai, Patrick Schweigler, Birk Poller, et al.
Clinical Pharmacology in Drug Development|October 5, 2021
Pharmacokinetics of Asciminib When Taken With Imatinib or With FoodMatthias Hoch, Julia Zack, Michelle Quinlan, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Drug Metabolism and Personalized Therapy|October 9, 2016
Improvement of the chemical inhibition phenotyping assay by cross-reactivity correctionNicholas M Njuguna, Ken-Ichi Umehara, Felix Huth, et al.
Drug Metabolism and Personalized Therapy|May 31, 2019
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissionsKenichi Umehara, Felix Huth, Yi Jin, et al.
Clinical and Translational Science|June 27, 2026
PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of SiponimodFelix Huth, Kasra Shakeri-Nejad, Anne Gardin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 15, 2024
Improving In Vitro-In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound MoleculesMarkus Trunzer, Joana Teigão, Felix Huth, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 13, 2019
Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical modelsJulia Riede, Ken-Ichi Umehara, Patrick Schweigler, et al.
Journal of Pharmaceutical Sciences|February 4, 2021
Predicting Oral Absorption for Compounds Outside the Rule of Five Property SpaceFelix Huth, Norbert Domange, Birk Poller, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 23, 2024
Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major MetabolitesUlrike Glaenzel, Felix Huth, Fabian Eggimann, et al.
Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 10, 2019
A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant TransportersPéter Tátrai, Patrick Schweigler, Birk Poller, et al.
Clinical Pharmacology in Drug Development|October 5, 2021
Pharmacokinetics of Asciminib When Taken With Imatinib or With FoodMatthias Hoch, Julia Zack, Michelle Quinlan, et al.
Pageof 5